İlko İlaç San. ve Tic. A.Ş.

The activities of Selçuklu Holding and its subsidiary İlaç San. ve Tic. A.Ş. in the sector are rooted in the pharmacy business of Mustafa Öncel, the honorary chairman and a second-generation pharmacist in Türkiye. Starting in the 1960s with the production of majistral, his investments in the pharmaceutical sector have been foundational to their operations. Pharmacist Mustafa Öncel's investments in the pharmaceutical industry since 1973 have led to successful sales and international partnerships. This knowledge and expertise spanning more than half a century continue today with İLKO Pharmaceuticals, which commenced operations in 2012 to maintain Selçuklu Holding's legacy in the sector and propel it to new heights.

İLKO Pharmaceuticals focuses on value-added and innovative products within the healthcare sector. It conducts biotechnological medicine development through İLKOGEN and operates in consumer health under the WELLCARE brand.

İLKO Pharmaceuticals serves both the domestic and global markets with nearly 1000 employees, offering 184 products spanning 90 different molecules.

Its production facilities represent the largest pharmaceutical investment in Anatolia. Facilities feature smart building capabilities and equipment compliant with CFR Part 11 standards. These facilities boast a production capacity of 120 million boxes annually in a single shift, supported by a robust quality assurance system.

ILKO Pharmaceuticals' production facilities are recognized for their exceptional quality and hold GMP certificates from the Turkish Ministry of Health, European authorities, and the Russian Ministry of Health, validating their adherence to rigorous international standards.

Situated in Çerkezköy, İLKOPOL is ILKO Pharmaceuticals' new production facility for cytotoxic products and was established with domestic capital. İLKO Pharmaceuticals has entered the oncology and TNF market with a robust product portfolio and continues to expand its offerings in this sector.

The company conducts its research and development activities at two separate centers. İlko Argem R&D Center in Ankara focuses on developing small molecule generic products, various food supplements, and support products. This center specializes in advanced technology-based products such as Core-In Tablets and Bilayer tablets.

İLKO Argem Biotechnology Center is Türkiye's first biotechnology R&D center. Currently, the center is conducting R&D and clinical studies on four biotechnological products aimed at cancer and related diseases.

ILKO Pharmaceuticals has invested 52 million euros in R&D to date, positioning itself as the 7th highest pharmaceutical company in Türkiye in terms of R&D spending.

The primary objective of Wellcare, the consumer health brand of ILKO Pharmaceuticals, is to provide consumers with "The Art of Living with Health." This entails offering reliable products supported by scientific research and approved by authorities to enhance the quality of life at every stage of our daily lives.

ILKO Pharmaceuticals exports to 36 countries and engages in licensing activities in more than 40 countries, along with strategic collaborations with international companies through contract manufacturing.

The company intends to become a leading global contender through its production and R&D investments, while focusing on "innovative" products that enhance the quality of life and contribute to life-saving advancements with the cutting-edge technologies essential in modern medicine.